TY - JOUR
T1 - Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 2.2024
AU - Wierda, William G.
AU - Brown, Jennifer
AU - Abramson, Jeremy S.
AU - Awan, Farrukh
AU - Bilgrami, Syed F.
AU - Bociek, Greg
AU - Brander, Danielle
AU - Cortese, Matthew
AU - Cripe, Larry
AU - Davis, Randall S.
AU - Eradat, Herbert
AU - Fakhri, Bita
AU - Fletcher, Christopher D.
AU - Gaballa, Sameh
AU - Hamid, Muhammad Saad
AU - Hill, Brian
AU - Kaesberg, Paul
AU - Kahl, Brad
AU - Kamdar, Manali
AU - Kipps, Thomas J.
AU - Ma, Shuo
AU - Mosse, Claudio
AU - Nakhoda, Shazia
AU - Parikh, Sameer
AU - Schorr, Andrew
AU - Schuster, Stephen
AU - Seshadri, Madhav
AU - Siddiqi, Tanya
AU - Stephens, Deborah M.
AU - Thompson, Meghan
AU - Ujjani, Chaitra
AU - Valdez, Riccardo
AU - Wagner-Johnston, Nina
AU - Woyach, Jennifer A.
AU - Sundar, Hema
AU - Dwyer, Mary
N1 - Publisher Copyright:
© 2024 Harborside Press. All rights reserved.
PY - 2024/4
Y1 - 2024/4
N2 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent’s toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.
AB - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent’s toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.
UR - http://www.scopus.com/inward/record.url?scp=85190904274&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2024.0018
DO - 10.6004/jnccn.2024.0018
M3 - Article
C2 - 38626800
AN - SCOPUS:85190904274
SN - 1540-1405
VL - 22
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 3
ER -